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Abstract 
In the literature data on the effect of renal impairment on the pharmacokinetics of anticancer drugs 
are scarce. Here, we report a 68 year old metastatic osteosarcoma patient with impaired renal 
function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m2 
cetuximab.  Pharmacokinetic parameters after the first dose, including dose normalised AUC from 
time zero to day 7 (AUC0-7), clearance (Cl), elimination half-life (t1/2) were estimated using trapezoidal 
non compartmental methods and compared to pharmacokinetic data from a study population with 
normal kidney function. These results showed that the pharmacokinetics of cetuximab in this patient 
with renal failure was similar to that with adequate renal function and suggests that cetuximab can 
be safely used in cancer patients with renal impairment without dose adjustment. 
Introduction 
Cetuximab is a monoclonal antibody, targeting epidermal growth factor receptor (EGFR) and 
registered for the treatment of colorectal and head and neck cancer.  During its development, the 
drug has been investigated in patients with adequate renal and hepatic function only and a dose of 
250 mg/m2 every week, after an initial loading dose of 400 mg/m2, is defined in the summary of 
product characteristics.  
No specific dose recommendations are given for patients with renal impairment 
(http://packageinserts.bms.com/pi/pi_erbitux.pdf ). The elimination of antibodies occurs via both 
nonspecific intracellular catabolism, following fluid-phase endocytosis, and receptor-mediated 
elimination after binding to their target antigen.   Part of cetuximab clearance is therefore explained 
by binding to EGFR. Clearance of the EGFR antibody cetuximab seems independent of the liver and 
kidney function [Do you have references?]. In addition, there are 4 case reports [2-5] of 
haemodialysis patients who could safely be treated with standard doses of cetuximab. The aim of 
this study was to determine the pharmacokinetics of conventional dose cetuximab in patients with 
impaired renal function and to compare it to published data obtained in populations of cetuximab 
treated patients with normal renal function.  
 
Method 
Case presentation 
We treated a 68 year old metastatic osteosarcoma patient with impaired renal function due to prior 
chemotherapy on compassionate use basis with 400 mg/m2 cetuximab. This treatment was based on 
preclinical data on cetuximab activity in osteosarcoma [6] and the lack of other treatment options. 
The medical ethical committee approved the treatment and the pharmacokinetic analysis and the 
patient gave informed consent. The starting dose was 740 mg, preceded by the recommended 2 mg 
of the antihistamine clemastine, to avoid an allergic reaction to cetuximab.  
Sample collection 
 Cetuximab was infused over two hours. Serum samples were collected 2, 3.5, 4.5, 44 and 168 hours 
after the end of the infusion in line with a previous pharmacokinetic study [7]. Cetuximab serum 
concentrations were measured using a validated immunoassay [8].  Limit of detection was 0.012 
mg/L and lower limit of quantitation (LLOQ) was 0.75 mg/L.  
Pharmacokinetic parameters 
Pharmacokinetic parameters after the first dose, including dose normalised AUC from time zero to 
day 7 (AUC0-7), clearance (Cl), elimination half-life (t1/2) were estimated by trapezoidal non 
compartmental methods using MW/PHARM 3.5 (Mediware, Groningen, The Netherlands). Results 
were compared to historical data on cetuximab in patients with normal renal function as reported by 
Tan et al.[9] and Fracasso et al.[10]. 
Results 
The maximum concentration (Cmax), measured at the end of the 2 hour infusion, in this patient was 
297 µg/mL, the minimum concentration (Cmin or through level) was 34.4 µg/mL. The reported 
serum concentration profile, shown in figure 1, was used to calculate the AUC, Cl and t ½. In table 
1,an overview of the pharmacokinetics of cetuximab in study populations with normal renal function 
and in this case is shown [2;9;10]. In this table the pharmacokinetics after a single dose of 400 
mg/m2 are depicted, and are used for comparison. 
In this patient the calculated AUC after the first dose was 20,280 µg*day/mL. The half-life after a 
single dose of cetuximab was 53.2 hours with a calculated clearance of 32.6 mL/h. The Cmax was 
approximately 30%  higher compared to the Cmax in the studies of Tan et al. and Fracasso et al. (6-7) 
The other parameters Cl, AUC, T1/2 and V are comparable as reported in those 2 studies. The half-life 
of cetuximab in our patient is 30% shorter than that calculated in the studies.  
During the first course of cetuximab, the patient experienced adverse effects:  reversible grade 2 
hallucinations and fatigue. After careful considerations these symptoms were deemed to be most 
likely caused by the 2 mg clemastine. Due to these side effects the patient refused further treatment 
with cetuximab. Little is known about the pharmacokinetics of clemastine, nonetheless, normally no 
dose reductions are advised in patient with renal impairment. 
Cetuximab-related side effects such as skin toxicity and diarrhoea did not occur in this patient during 
the first course. 
 
Discussion 
This case report shows that the pharmacokinetics of cetuximab in a patient with renal failure is 
similar to that with adequate renal function. Different studies investigated the pharmacokinetics of 
cetuximab in population with adequate renal function. For the comparison, studies with single doses 
were used. Most of the studies reported cetuximab pharmacokinetic parameters at steady state 
after a loading dose of 400 mg/m2 followed by weekly doses of 250 mg/m2. Using a loading dose, 
steady state is usually reached within three weeks. Since this patient discontinued therapy after one 
single infusion, we can only compare this single dose to similar administrations available in the 
literature. 
Our study shows some difference between the estimated parameters in our patient and patients 
with normal renal function. Due to inter patient variability, nonetheless, overall the kinetic profile is 
in line with the population with adequate renal function. Cetuximab pharmacokinetics are not 
studied in patients with impaired renal function, four case reports [2-5] studied the kinetics of 
cetuximab in patients undergoing haemodialysis. These four case studies showed that cetuximab in 
a patient with haemodialysis may be safely used. The estimated pharmacokinetic parameters were 
comparable to cetuximab patients with normal kidney function. Our study shows, for the first time, 
that pharmacokinetic parameters were also not altered in a patient with decreased renal function 
without haemodialysis. 
Many drugs that enter the market are studied in a patient population with normal renal function and 
no dose recommendations are made for patients with impaired organ function and formal organ 
impairment studies are lacking. This is also the case for cetuximab. Other than from common sense 
and four case reports in haemodialysis patients there was no information available to guide our 
decision on how to use cetuximab in this patient. As renal impairment is a common problem in head 
and neck cancer patients due to prior cisplatin chemotherapy and in colorectal cancer patients due 
to the high incidence of the disease our finding of no clinically relevant alteration of cetuximab 
pharmacokinetics in our patient with impaired renal function has clinical importance for dose 
guidance in future patients. 
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 Study model Dose Cmax 
 µg/mL 
Cmin  
µg/mL 
AUC0-7 
h*mg/L 
CL  
mL/h 
T ½ 
Hours  
V 
Litre 
Case Non 
compartmental 
model 
740 mg 
(400 
mg/m2) 
297.0  34.4  20.280  32.6  53.2  2.48 
Tan et al. 
2006 
Non 
compartmental 
model 
400 mg/m2 
single dose 
205.0 (65.7) 
(µg/mL) 
n/a 19,000 
(7,802)  
21.5 (7.68) 75.10 (15.9)  2.44 (0.43)  
Fracasso et al. 
2007 
  
Non 
compartmental 
model 
400 mg/m2 
single dose 
228.9 (6,5) 
µg/mL 
n/a 24,620 
(9,555) 
43.6 (15.8) 
mL/h 
97.5 (20.7) h 4.8 (2.2) 
Table 1: Pharmacokinetic parameters of the case and historical data from two studies 
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Figure 1: Time curve of serum cetuximab concentration following two hour infusion of 740 mg cetuximab in a patient with a glomerular filtration rate of 
approximately 30 mL per minute. 
